confidently live life with ease Management Presentation 1 - PowerPoint PPT Presentation

confidently live life with ease Management Presentation 1

Forward-Looking Statements These statements involve known and unknown risks, uncertainties and other factors that may This presentation contains certain forward-looking statements cause our actual results, levels of activity, performance or achievements to be materially different that involve risks and uncertainties that could cause actual from the information expressed or implied by these forward- looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this results to be materially different from historical results or from presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. any future results expressed or implied by such forward- Factors that may cause actual results to differ materially from any future results expressed or looking statements. implied by any forward-looking statements include the risk that we may not achieve greater market acceptance of our Eversense™ System; the risk that we may not be able to establish sales and marketing capabilities in order to meet demand for our Eversense™ System; risks associated with competition in the diagnostics industry; risks associated with the performance of our Eversense™ System; the risk that we may not receive regulatory clearance for our Eversense ™ System in the United States; the risk that we may not be able to comply with extensive ongoing regulatory In some cases, you can identify forward- looking statements by the words “expect,” “intend,” “target,” requirements; risks associated with reliance on a limited number of suppliers; the risk that we may “plan,” “estimate,” “predict,” “opportunity,” and “continue,” or the negative of these terms, or other not be able to successfully develop or introduce new or other applications of our technology at all or comparable terminology intended to identify statements about the future. Forward-looking in a timely manner; the risk that we may not be able to maintain and expand coverage and statements include statements about future demand for our Eversense™ System and future reimbursement from health insurers and other third-party payers; risks associated with limited products, if any, that we may develop; the growth of the CGM market; the factors that we believe patent protection; the risk that we may not successfully manage our growth; and risks associated drive demand for our Eversense™ System and our ability to sustain such demand; the size of the with reliance on outside financing to meet capital requirements. For further information regarding market and competitive landscape for our Eversense™ System; the initiation, timing, progress and these risks, uncertainties and other factors you should read the “Risk Factors” section of our results of our clinical trials; our plans for the Eversense™ System and our expectations about Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Report on completion of its development and the timing of the submission for regulatory approval by the FDA, Form 10-Q for the quarter ended June 30, 2016 and our other filings we make with the Securities and the timing for receiving such approvals; our enhancement of the Eversense™ System, and Exchange Commission from time to time. including the extension of sensor life and improvements in accuracy; launch of the Eversense™ Any forward-looking statements speak only as of the date of this presentation. We undertake no System in the United States and European countries; expected long-term gross profit margins; our obligation to publicly update any forward-looking statements, whether as a result of new plans for pursuing coverage and reimbursement for our Eversense™ System; our ability to protect information, future events or otherwise. and enforce our intellectual property rights; and anticipated trends and challenges in our business and the market in which we operate. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

confidently live life with ease . . . Develop and commercialize transformative glucose monitoring products. 3 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.

CGM Gives You Better Insight Eversense 350 Glucose Readings 300 SMBG 250 SMBG Glucose 200 HYPERGLYCEMIA Concentration SMBG 150 (mg/dL) SMBG Target Range 100 50 HYPOGLYCEMIA 0 8AM 12PM 4PM 8PM 12PM 4AM 14.00 22.00 0.00 2.00 4.00 6.00 8.00 10.00 Time 4 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.

The Market Is Quickly Growing CGM $8 10 fastest growing $6.5 $7 segment 8 $5.8 $6 Revenue In Billions Millions of Patients $5 6 Europe $3.5 $4 $3.3 Europe 4 $2.5 $3 $2 2 $0.7 $1 2020 2020 2020 2015 Est. 2015 Est. 2015 Est. U.S. U.S. $0 0 2015 2020 CGM* Insulin Pumps SMBG ~35 – 40% CAGR ~8% CAGR ~(2%) CAGR Intensively Managed Population Type 1 CGM penetration, in the US, projected to grow from 8% to 45% by 2020 5 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.

Opportunities to Improve Patient Acceptance top 5 reasons why people discontinue CGM... Real-Time Continuous Glucose 1 2 3 Monitoring Among Participants in the Discomfort Problems Problems TID Exchange when wearing inserting with Clinic Registry CGM sensor adhesive holding sensor on the skin 4 5 Wong J.C et al, Diabetes Care 2014;37:2702 – 2709 | DOI: 10.2337/dc14-0303 Accuracy Sensor skin reactions 6 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.

The Eversense System Sensor Smart Transmitter Mobile App Sensor that lasts up to 180 days No extra device to carry Removable and rechargeable No weekly sensor insertion iOS and Android platform On-body vibe alerts No open wound Alarm settings & reports Gentle-on-skin adhesive 7 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.

Established, Proven Biocompatible Encasement Sensor Technology Optical Interface Non-enzymatic, fluorescence Polymer based measurement Hydrogel Simple in-office procedure – less than 5 mins NFC Antenna Best-in-class accuracy no weekly sensor Lasts up to 180-days no open insertion without removing wound no sensor Tested in over 900 sensors in 500 wasted patients, 100,000 sensor wear days when transmitter removed 8 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.

on body alerts for extra security 9 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.

Eversense Mobile Platform Enables Advanced Features Predictive Low/High Glucose Alerts & Remote Monitoring Rate of Change Alerts Reports Directly on App with Eversense Now Readings on Applewatch Email PDF report to caregiver 10 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.

Industry leading accuracy U.S. PRECISE II Study Completed • Determine safety and MARD accuracy 8.8 % • Prospective, single-arm multi-center investigation • 90 adults with diabetes Glucose range of 40-400 mg/dL • 1 sensor inserted for 90 days in upper arm Throughout 90-day use largest continuous single-sensor • Utilized improved glucose algorithm pivotal study in the world • Data for PMA submission 16,000+ paired data points, 2,000,000+ sensor glucose readings 11 Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States.